{"name":"Neurology Center of New England P.C.","slug":"neurology-center-of-new-england-p-c","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Abobotulinumtoxin A","genericName":"Abobotulinumtoxin A","slug":"abobotulinumtoxin-a","indication":"Cervical dystonia","status":"phase_3"}]}],"pipeline":[{"name":"Abobotulinumtoxin A","genericName":"Abobotulinumtoxin A","slug":"abobotulinumtoxin-a","phase":"phase_3","mechanism":"Abobotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Hemifacial spasm","Spasticity","Chronic migraine"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1aUUkzbmU5aHE0SjMwMl9fd1RMZE8xeFJRZG42OTkxbkdSakNDcXMwcHRxREIzR0x0U1ZzS29falVxaV85Zi1aczUzT2pBRVlpQ1pEVDBCTXB6Wm1vRkZxTUdoS1ZnV3pZc21vbTVzMy1aQ0VS?oc=5","date":"2019-01-18","type":"pipeline","source":"Fortune","summary":"Could This Radical New Approach to Alzheimer’s Lead to a Breakthrough? - Fortune","headline":"Could This Radical New Approach to Alzheimer’s Lead to a Breakthrough?","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}